Pharma Leaders Navigate Patent Cliffs Through M&A and AI Integration, Conference Shows

Healthcare executives gathered at the Morgan Stanley Global Healthcare Conference to discuss strategies for managing major patent expirations and sustaining growth through acquisitions and artificial intelligence implementation. The industry is directing significant capital toward high-growth areas including oncology, cell therapy, and cardiometabolic treatments, with strategic buyers accounting for approximately 70 percent of healthcare deal activity. Biopharma firms are also developing next-generation therapies such as oral formulations and extended-release treatments to differentiate from commoditized first-generation drugs.

The pharmaceutical industry faces a critical inflection point as major revenue-generating drugs lose patent protection within the next several years. To counter this threat, companies are pursuing two parallel strategies: acquiring smaller biotech firms with promising pipelines and investing heavily in therapeutic areas with strong growth trajectories, particularly cancer treatments and metabolic disease management. These acquisitions have become the dominant force in healthcare deal-making, with strategic pharmaceutical buyers orchestrating approximately seven of every ten transactions in the sector.

The competitive differentiation increasingly depends on innovation beyond standard treatments. Rather than relying on first-generation formulations, firms are developing improved versions—such as pills instead of injections or longer-acting formulations—while simultaneously exploring emerging therapeutic approaches. Simultaneously, machine learning and data analytics are reshaping how companies discover drugs and operate clinically, with organizations leveraging accumulated patient records and genomic information to accelerate research timelines and reduce development costs.